FDA Approves Aurlumyn for Severe Frostbite Treatment.

The FDA greenlights Aurlumyn, or iloprost, as an injectable treatment for severe frostbite, aiming to mitigate amputation risks in affected adults. Developed by Actelion Pharmaceuticals U.S., Inc., Aurlumyn's approval, expedited due to the rarity of severe frostbite cases, marks a significant milestone. Originally used for pulmonary arterial hypertension, iloprost's ability to dilate blood vessels and prevent clotting now offers hope for improved blood flow and tissue preservation in frostbite patients. Dr. Norman Stockbridge heralds the approval as a breakthrough, providing the first-ever treatment option for severe frostbite.